PRLX Announces Intent to Develop a Rapid Screening Test for COVID-19 on its Patented FDA 510(K) Approved Diagnostic Platform
March 11 2020 - 7:38AM
InvestorsHub NewsWire
PRLX Announces Intent to Develop a
Rapid Screening Test for COVID-19 on its Patented FDA 510(K)
Approved Diagnostic Platform
Company will Partner to Accelerate The
Deployment of Diagnostic Solutions Under Patent Protected Service
Areas Including China, Hong Kong, India, and
US
NEW YORK, NY -- March 11, 2020 -- InvestorsHub NewsWire
-- Parallax Health Sciences,
Inc. (PRLX)
(''Parallax'' or the ''Company''), an outcome-driven connected
healthcare company, today announced its wholly owned subsidiary
Parallax Diagnostics, Inc. will execute a partnership strategy to
develop, acquire or license monoclonal and polyclonal antibodies
for the creation of a low cost and rapid screening test for
COVID-19 (coronavirus disease 2019) to be delivered in conjunction
with the manufacturing and distribution of the Company’s patented
and proven VT-1000 Immunoassay diagnostic platform.
Dr. David Stark, President of Parallax Diagnostics, stated, “We
are seeking partners to accelerate developing a rapid screening
test for COVID-19 to meet the urgent demand on a global basis.” Dr.
Stark went on to say, “Parallax is uniquely positioned with its FDA
510(K) approved and patented platform to provide low cost and
accurate rapid point of care screening tests within patients in
mobile and remote environments.”
The COVID-19 outbreak is being closely monitored by the Centers
for Disease Control (“CDC)” and the World Health Organization
(“WHO”). Parallax Diagnostics is in discussions with both
organizations along with private laboratories and universities to
assist in facilitating its participation in providing diagnostic
solutions for the creation and deployment of mobile rapid screening
tests. As an FDA 510(K) approved solution, the Parallax
Diagnostics platform goal is to help the medical community to
address and combat pandemic viruses and other illnesses through
rapid screening tests that are accurate, low in cost and broadband
data connected so that remote diagnostics can be performed and
reported in real-time and integrated with existing
Internet-of-Things, (“IoT”) devices.
Parallax Diagnostics’ goal is in accelerating the development of
solutions that aid the medical communities in the United States,
China, India, UK, Australia, and other countries.
The following patent families will support this development
effort to obtain market share positions in these countries:
- FDA Approved and Patented Sparks Handheld Diagnostic
Device “Portable Apparatus for Sample Analysis” Patent Numbers CN
101558302, HK 1137813, IN 279743, MO J001298, GB2526749,
WO2014144749A1
- Patented Good Health Outcomes Remote Patient Monitoring
Systems “Data Driven Outcomes” Patent numbers AU2020100161 (A4)
GB2526749 (A) US10061812 (B2) US2014280136 (A1) US2018373763
(A1)
About Parallax Diagnostics
Parallax Diagnostics is a bio-medical company and wholly owned
subsidiary of Parallax Health Sciences, Inc. Parallax Diagnostics
owns a line of 26 FDA approved, Point of Care diagnostic tests on a
single platform in the area of infectious disease, cardiac, medical
conditions, drugs of abuse, and pregnancy. Parallax
Diagnostics is developing a novel, handheld diagnostic testing
system that is simple, rapid and elegant, offering the potential to
transform the diagnostic landscape by transitioning critical tests
from the centralized lab directly to the hands of the physician or
clinicians. Our focus is on tests that detect and/or monitor
infectious diseases.
About Parallax Health Sciences
Parallax Health Sciences is a leading-edge technology,
outcome-driven telehealth company that allows for cost-effective
remote diagnosis, treatment, and monitoring of patients through
proprietary platforms of integrated products and services. The
Company's interoperable novel applications provide patients
point-of-care testing and monitoring with information communicated
via internet-based mobile phone applications that are agnostic as
to operating system and are built on highly sophisticated data
analytics. Information is retrieved real-time by physicians who are
monitoring patients with chronic diseases or through biometric
feedback for health-related behavior modification, and is automated
for integration into electronic health records. The Company's
products and offerings capitalize on the digital transformation in
healthcare for improved patient compliance, diagnosis and
treatment, and support healthcare system cost savings and
efficiencies. For more information, please
visit www.parallaxhealthsciences.com or www.parallaxcare.com.
Forward-Looking Statements
This release includes forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended.
All statements regarding our expected future financial position,
results of operations, cash flows, financing plans, business
strategy, products and services, competitive positions, growth
opportunities, plans and objectives of management for future
operations, as well as statements that include words such as
"anticipate," "if," "believe," "plan," "estimate," "expect,"
"intend," "may," "could," "should," "will," and other similar
expressions are forward-looking statements. All forward-looking
statements involve risks, uncertainties and contingencies, many of
which are beyond our control, which may cause actual results,
performance, or achievements to differ materially from anticipated
results, performance, or achievements. Factors that may cause
actual results to differ materially from those in the
forward-looking statements include those set forth in our Form 10-K
and other reports filed with the SEC. We are under no obligation to
(and expressly disclaim any such obligation to) update or alter our
forward-looking statements, whether as a result of new information,
future events or otherwise.
Investor
Contact:
Paul Arena,
CEO
paul@parallaxcare.com
cell
404-915-8449
Parallax Health Sciences (CE) (USOTC:PRLX)
Historical Stock Chart
From May 2024 to Jun 2024
Parallax Health Sciences (CE) (USOTC:PRLX)
Historical Stock Chart
From Jun 2023 to Jun 2024